Immune response


Last updated: 2021 Aug 3
Total hit(s): 16
Select item(s)
Key Findings
Comments
(You can add your comments too!)
Original Article
(hover to see details)
In a randomised, placebo-controlled phase 1 trial, S protein subunit vaccine SCB-2019 without adjuvant had a poor immunogenic response with 3 seroconversions by day 50. However, with adjuvants- either AS03 or CpG/Alum a good humoral and cellular responses were elicited. Based on these results, 9 g SCB-2019 adjuvanted with AS03 and 30 g SCB-2019 adjuvanted with CpG/Alum are the preferred candidates for the phase 2/3 trials. All the formulation had a good safety profile.
33524311
(Lancet)
PMID
33524311
Date of Publishing: 2021 Feb 20
Title Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial
Author(s) nameRichmond P, Hatchuel L et al.
Journal Lancet
Impact factor
43.38
Citation count: 2
Date of Entry 2021 Aug 3


In an open, non-randomised, combined phase 1/2 trial, heterologous vector-based vaccine rAd26 and rAd5 COVID vaccines induced strong humoral and cellular immune responses.
32896291
(Lancet)
PMID
32896291
Date of Publishing: 2020 Sep 26
Title Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia
Author(s) nameLogunov DY, Dolzhikova IV et al.
Journal Lancet
Impact factor
43.38
Citation count: 65
Date of Entry 2021 Aug 3


In a placebo-controlled, randomised, double-blind phase 2 clinical trial of Adv5 vectored COVID-19 vaccine, it was found that a single dose of 510^10 viral particles was significantly immunogenic. The vaccine-induced seroconversion of neutralising antibodies and good T cell responses.
32702299
(Lancet)
PMID
32702299
Date of Publishing: 2020 Aug 15
Title Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial
Author(s) nameZhu FC, Guan XH et al.
Journal Lancet
Impact factor
43.38
Citation count: 81
Date of Entry 2021 Aug 3


In a phase 1/2 trial, ChAdOx1 nCoV-19 vaccine induced both cellular and humoral immune responses. Spike-specific T cells responses were detectable by day 14 and spike-specifc IgG antibodies were detectable by day 28. Both responses were boosted after the second dose. Neutralising antibody responses were seen in all participants after the booster dose.
32702298
(Lancet)
PMID
32702298
Date of Publishing: 2020 Aug 15
Title Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
Author(s) nameFolegatti PM, Ewer KJ et al.
Journal Lancet
Impact factor
43.38
Citation count: 162
Date of Entry 2021 Aug 3


In phase 1 trial for an inactivated vaccine BBV152, the high neutralising antibody response elicited in phase 1 participants remained elevated even after three months. In the phase 2 trial participants, a better humoral and cell-mediated immune response was produced. The phase 3 trials would be conducted with the 6ug-Algel-IMDG formulation. The study was conducted at a time when the number of COVID-19 cases was increasing in India. The participants in the study could have been exposed to possible infection. In case of such natural exposure to the virus, it is possible the antibody titre values were slightly inflated
33705727
(Lancet Infect Dis)
PMID
33705727
Date of Publishing: 2021 Mar 8
Title Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial
Author(s) nameElla R, Reddy S et al.
Journal Lancet Infect Dis
Impact factor
21.77
Citation count: 9
Date of Entry 2021 Jun 22


In phase 1, double blind, randomised trial, the immune response of the BBV152 vaccine was investigated. The vaccine was able to elicit a good immune response.
33485468
(Lancet Infect Dis)
PMID
33485468
Date of Publishing: 2021 Jan 21
Title Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial
Author(s) nameElla R, Vadrevu KM et al.
Journal Lancet Infect Dis
Impact factor
21.77
Citation count: 1
Date of Entry 2021 Jun 22


In a placebo-controlled, observer-blinded, dose-escalation, phase 1 trial, the two vaccine candidates; BNT162b1 and BNT162b2 were observed to have similar immunogenicity. The SARS-CoV-2-neutralizing geometric mean titers, obtained in both the vaccine groups were similar to SARS-CoV-2 convalescent serum samples.
33053279
(N Engl J Med)
PMID
33053279
Date of Publishing: 2020 Dec 17
Title Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
Author(s) nameWalsh EE, Frenck RW Jr et al.
Journal N Engl J Med
Impact factor
37.91
Citation count: 46
Date of Entry 2021 Jun 22


In phase 1, the dose-escalation trial, the immune response of the mRNA-1273 vaccine was assessed. The 100ug dose of the vaccine elicited higher binding- and neutralizing-antibody response than the 25ug dose. Hence, 100ug of the vaccine was used in phase 3.
32991794
(N Engl J Med)
PMID
32991794
Date of Publishing: 2020 Dec 17
Title Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
Author(s) nameAnderson EJ, Rouphael NG et al.
Journal N Engl J Med
Impact factor
37.91
Citation count: 62
Date of Entry 2021 Jun 22


In a dose-escalating phase 1 trial, Ad5 vectored COVID-19 vaccine was found to be well-tolerated and immunogenic at 28 days post-vaccination. T cell responses were seen 14-days post-vaccination. Some patients in all three groups had high pre-existing Ad5 neutralising antibody titre. The pre-existing antibody titre had a negative impact on the pattern of T cell responses.
32450106
(Lancet)
PMID
32450106
Date of Publishing: 2020 Jun 13
Title Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial
Author(s) nameZhu FC, Li YH et al.
Journal Lancet
Impact factor
43.38
Citation count: 205
Date of Entry 2021 Jun 22


In a phase2/3 trial of the ChAdOx1 nCoV-19 vaccine, immunogenecity was found to be similar across all age groups after the booster dose.
33220855
(Lancet)
PMID
33220855
Date of Publishing: 2021 Dec 19
Title Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial
Author(s) nameRamasamy MN, Minassian AM et al.
Journal Lancet
Impact factor
43.38
Citation count: 26


In a phase1/2 clinical trial, BBIBP-CorV inactivated vaccine given in a 2 dose regimen was found to be safe and well-tolerated. The vaccine-induced a robust humoral response in 100% of the vaccine recipients.
33069281
(Lancet Infect Dis)
PMID
33069281
Date of Publishing: 2021 Jan
Title Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial
Author(s) nameXia S, Zhang Y et al.
Journal Lancet Infect Dis
Impact factor
21.77
Citation count: 17


In a phase1/2 clinical trail, BBIBP-CorV inactivated vaccine given in a 2 dose regimen was found to be safe and well tolerated. The vaccine induced a robust humoral response 1n 100% of the vaccine recipients.
33069281
(Lancet Infect Dis)
PMID
33069281
Date of Publishing: 2021 Jan
Title Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial
Author(s) nameXia S, Zhang Y et al.
Journal Lancet Infect Dis
Impact factor
21.77
Citation count: 17


In a placebo-controlled, observer-blinded, pivotal efficacy trial, nucleoside-modified RNA vaccine BNT162b2 was found to be 95% effective in preventing COVID-19 infection.
33301246
(N Engl J Med)
PMID
33301246
Date of Publishing: 2020 Dec 31
Title Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Author(s) namePolack FP, Thomas SJ et al.
Journal N Engl J Med
Impact factor
37.91
Citation count: 67


The INO-4800 DNA vaccine was immunogenic in 100% (38/38) of the vaccinated subjects. The vaccine elicited both cellular and humoral immune responses in all subjects. The INO-4800 DNA Vaccine was found to be safe and induced both cellular and humoral immune responses in the vaccine recipients.
33392485
(EClinicalMedicine)
PMID
33392485
Date of Publishing: 2020 Dec 24
Title Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trial
Author(s) nameTebas P, Yang S et al.
Journal EClinicalMedicine
Impact factor
6.68
Citation count: 2


In a phase 1/2 trial, NVX-CoV2373, a recombinant severe acute respiratory syndrome coronavirus 2 (rSARS-CoV-2) nanoparticle vaccine was found to be safe and elicited an immune response that exceeded levels in COVID-19 convalescent serum. By day 35, a strong correlation was observed between neutralising antibody titres and anti-spike IgG Geometric mean ELISA units (GMEs) with adjuvanted vaccine (correlation, 0.95). This was comparable to that of convalescent serum (correlation, 0.96).
32877576
(N Engl J Med)
PMID
32877576
Date of Publishing: 2020 Dec 10
Title Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine
Author(s) nameKeech C, Albert G et al.
Journal N Engl J Med
Impact factor
37.91
Citation count: 72


In a phase I/II study of COVID-19 RNA vaccine BNT162b1 showed good immunogenicity and showed a good amount of RBD-binding IgG titers.
32785213
(Nature)
PMID
32785213
Date of Publishing: 2020 Oct
Title PhaseI/II study of COVID-19 RNA vaccine BNT162b1 in adults
Author(s) nameMulligan MJ, Lyke KE et al.
Journal Nature
Impact factor
24.36
Citation count: 49